Anzeige
Meldung des Tages: Drohnenkrieg definiert Sicherheit neu: Herausforderungen für Rheinmetall und AeroVironment – Nachzügler Volatus Aerospace

Teva Pharma Aktie (ADR) News

Aktie
WKN:  883035 ISIN:  US8816242098 US-Symbol:  TEVA Branche:  Pharmazeutika Land:  Israel
24,80 €
-0,2 €
-0,80%
30.03.26
Depot/Watchlist
Marktkapitalisierung *
31,15 Mrd. €
Streubesitz
39,66%
KGV
-15,52
Faktor
1
Originalaktie
IL0006290147
Nachhaltigkeits-Score
58 %
Weiter abwärts? Short handeln - Jetzt mit Hebel 21,95: WA13SV
Werbung

Teva Pharmaceutical Aktie (ADR) News

30.03.26 - GlobeNewswire
Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab)
Tevas Biosimilar PONLIMSI™ ist nun von der FDA für alle Indikationen des Referenzprodukts Prolia ® (Denosumab) zur Behandlung verschiedener schwerer Knochenerkrankungen ...
30.03.26 - GlobeNewswire
Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab)
Tevas Biosimilar PONLIMSI™ ist nun von der FDA für alle Indikationen des Referenzprodukts Prolia ® (Denosumab) zur Behandlung verschiedener schwerer Knochenerkrankungen ...
30.03.26 - GlobeNewswire
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
Teva’s biosimilar, PONLIMSI™, is now FDA-​approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of debilitating bone conditions. Teva’s ...
19.03.26 - GlobeNewswire
Teva Releases Q1 2026 Aide Memoire
TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available ...
19.03.26 - GlobeNewswire
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a ...
03.03.26 - GlobeNewswire
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1A Duvakitug is currently in phase 3 clinical ...
24.02.26 - GlobeNewswire
Teva to Present at the Upcoming Investor Conferences in March
PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, ...
20.02.26 - GlobeNewswire
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Olanzapine long-​acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-​monthly, subcutaneous formulation 1 If approved, TEV-...
17.02.26 - GlobeNewswire
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of ...
28.01.26 - GlobeNewswire
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-​over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to ...
27.01.26 - GlobeNewswire
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
Actor and comedian, Will Forte, opens up about his brother-​in-law's journey with Huntington’s disease (HD) and chorea through Teva’s Honestly HD program HD is a rare, ...
26.01.26 wallstreetONLINE Redaktion
Streit um Diabetes-Markt: Milliarden-Blockbuster unter Beschuss: Klage könnte Novo teuer zu stehen kommen
Eine Klage wirft Novo Nordisk vor, günstige Generika jahrelang blockiert zu haben. Im Zentrum steht ein Deal und der Milliardenumsatz eines Diabetesmittels.Der dänische ...
14.01.26 - GlobeNewswire
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-​related peptide (CGRP) antagonist treatment option for ...
12.01.26 - GlobeNewswire
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. ...
11.01.26 - GlobeNewswire
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 ...
05.01.26 - GlobeNewswire
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and ...
24.12.25 - GlobeNewswire
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline. Moody's affirmed Teva's B1a rating and revised Teva's ...
19.12.25 - GlobeNewswire
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
According to the settlement agreement, the proposed biosimilar to Eylea ® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier ...
12.12.25 - GlobeNewswire
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth ...
12.12.25 - GlobeNewswire
Teva Releases Q4 2025 Aide Memoire
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on ...

Newssuche

Videos

newspaper
30.03.26 -19,23%
Technical Trading 73% Trefferquote
GBP/USD Long Typ: Turbo Open End WKN: VG541T Hebel:30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »